Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Spermotrend in the Treatment of Male Infertility

This study has been completed.
Information provided by:
Catalysis SL Identifier:
First received: September 10, 2009
Last updated: March 6, 2011
Last verified: March 2011
The purpose of this study is to determine whether the administration of the dietary supplement Spermotrend improves spermatogenesis parameters in subjects with male infertility unrelated to major testicular conditions. The duration of this double-blind placebo controlled phase 3 clinical trial will be 24 weeks. The estimated number of males with infertility to be recruited and randomized for the study is 86.

Condition Intervention Phase
Male Infertility
Dietary Supplement: Placebo
Dietary Supplement: Spermotrend
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Assessment of the Efficacy of Dietary Supplement Spermotrend in the Treatment of Male Infertility

Resource links provided by NLM:

Further study details as provided by Catalysis SL:

Primary Outcome Measures:
  • Parameters of seminal analysis at weeks 24 [ Time Frame: 24 weeks ]

Secondary Outcome Measures:
  • Fertilization achievement [ Time Frame: 24 weeks ]
  • Presence of mild or severe adverse effects [ Time Frame: 24 weeks ]

Estimated Enrollment: 86
Study Start Date: September 2009
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Dietary Supplement: Placebo
One Placebo tablet (Orally administered) twice a day, for 12 weeks.
Experimental: Spermotrend Dietary Supplement: Spermotrend
One Spermotrend tablet (Orally administered) twice a day, for 12 weeks


Ages Eligible for Study:   19 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male infertility unrelated to major testicular conditions
  • Must have at least one altered seminal parameter.
  • Signed informed consent

Exclusion Criteria:

  • Hydrocele, varicocele, orchitis, epididymitis, irradiation or Chemotherapy.
  • Previously treated and cured testicular condition.
  • Non-transmissible chronic diseases
  • Use of antioxidant agents within 6 months.
  • Use of vitamins within 6 months.
  • Use of anti-inflammatory drugs within 6 months.
  • Use of hormones prescribed by an andrologist within 6 months
  • Positive serology/HIV
  • Leukocytospermia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00975117

"Ramón González Coro" Gynecologic and Obstetric Hospital
Havana, Cuba, 10400
Sponsors and Collaborators
Catalysis SL
Principal Investigator: Miguel Aguilar Charara, MD "Ramón González Coro" Gynecologic and Obstetric Hospital
  More Information

Responsible Party: Miguel Aguilar Charara, "Ramón González Coro" Gynecologic and Obstetric Hospital Identifier: NCT00975117     History of Changes
Other Study ID Numbers: CAT-0905-CU
Study First Received: September 10, 2009
Last Updated: March 6, 2011

Keywords provided by Catalysis SL:
Dietary supplement
male infertility

Additional relevant MeSH terms:
Infertility, Male
Genital Diseases, Male
Genital Diseases, Female processed this record on May 25, 2017